For many years the primary therapeutic aim in diabetes mellitus was to avoid acut complications. This view has slowly changed during the past 25 years, and trying to achieve normoglycaemia has become the main target of diabetes therapy accepted worldwide and supported by results of several prospective clinical trials in both types of diabetes. Our team has been following this principle for the past 20 years. According to our results it seems that throughout the long-term implementation of these methods, not only the intermediate outcome improves, but also less diabetes related endpoints will be experienced in the future, such as blindness or end-stage renal failure.
|Number of pages||6|
|Journal||Lege Artis Medicinae|
|Publication status||Published - febr. 24 2000|
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
ASJC Scopus subject areas